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Abstract
Fibroblast growth factor 23 (FGF-23) is known to be produced by the bone and linked to metabolic risk. We aimed to
explore circulating FGF-23 in association with fatness and insulin sensitivity, atherosclerosis and bone mineral density
(BMD). Circulating intact FGF-23 (iFGF-23) and C-terminal (CtFGF-23) concentrations (ELISA) were measured in 133 middle
aged men from the general population in association with insulin sensitivity (Cohort 1); and in association with fat mass and
bone mineral density (DEXA) and atherosclerosis (intima media thickness, IMT) in 78 subjects (52 women) with a wide range
of adiposity (Cohort 2). Circulating iFGF-23 was also measured before and after weight loss. In all subjects as a whole, serum
intact and C-terminal concentrations were linearly and positively associated with BMI. In cohort 1, both serum iFGF-23 and
CtFGF-23 concentrations increased with insulin resistance. Serum creatinine contributed to iFGF-23 variance, while serum
ferritin and insulin sensitivity (but not BMI, age or serum creatinine) contributed to 17% of CtFGF-23 variance. In cohort 2,
CtFGF-23 levels were higher in women vs. men, and increased with BMI, fat mass, fasting and post-load serum glucose,
insulin, HOMA-IR and PTH, being negatively associated with circulating vitamin D and ferritin levels. The associations of
CtFGF-23 with bone density in the radius, lumbar spine and carotid IMT were no longer significant after controlling for BMI.
Weight loss led to decreased iFGF-23 concentrations. In summary, the associations of circulating FGF-23 concentration with
parameters of glucose metabolism, bone density and atherosclerosis are dependent on iron and obesity status-associated
insulin resistance.
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Introduction
Fibroblast growth factor 23 (FGF-23) is a factor controlling
inorganic phosphate metabolism and mineralization. FGF-23 is an
approximately 32-kD (251 amino-acids) protein with an N-
terminal region that contains the FGF homology domain and a
novel 71-amino acid C-terminus. The discovery of FGF-23
revealed a tightly controlled system regulating serum phosphate.
This newly discovered regulation of serum phosphate by FGF-23
is independent of PTH or the vitamin D endocrine system. Recent
findings identify the skeleton as an endocrine organ and enable
several abnormalities of phosphate and vitamin D metabolism to
be classified as endocrine diseases [1].
Several studies have confirmed that bone is a primary site of
FGF-23 production, although FGF-23 was expressed in the
ventrolateral thalamic nucleus in mice [2], and weak FGF-23
expression was also observed in liver, heart, thymus and lymph
nodes [3]. FGF-23 protein is detected in human bone by
immunohistochemistry [4]. Recent results confirm that FGF-23
is produced by osteocytes in bone, circulates as a hormone and
acts on the kidney to influence phosphate metabolism and, hence,
bone mineralization [1,5–8].
High-phosphate diet increases and low-phosphate diet decreases
FGF-23 levels in human subjects [9]. High serum FGF-23 levels
are linked to adverse outcomes such as increased mortality in
patients receiving hemodialysis [10,11] and to mortality and
cardiovascular events in patients with coronary artery disease [12].
Higher FGF-23 levels, even in subjects with normal renal function,
are associated with cardiovascular risk factors such as vascular
dysfunction, atherosclerosis, and left ventricular hypertrophy [13–
17]http://atvb.ahajournals.org/cgi/content/full/31/1/219-B12#
B12http://atvb.ahajournals.org/cgi/content/full/31/1/219-B13#
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B13. Interestingly, circulating FGF-23 has also been recently
associated with some characteristics of the metabolic syndrome in
elderly individuals [18]. For this reason, we aimed to evaluate
circulating intact FGF-23 (iFGF-23) and C-terminal (CtFGF-23)
concentrations (ELISA) in association with metabolic parameters
such as fat mass, insulin sensitivity, bone mineral density and intima
media thickness. Circulating iFGF-23 was also measured before and
after weight loss.
Materials and Methods
Cohort 1
One hundred and thirty-three subjects (all men) were randomly
localized from a census and they were invited to participate. The
participation rate was 71%. A 75-g oral glucose tolerance test
(OGTT) according to the American Diabetes Association Criteria
was performed in all subjects.
Inclusion criteria were 1) BMI,40 kg/m2, 2) absence of
systemic disease, and 3) absence of infection within the previous
month. None of the control subjects were under medication or had
evidence of metabolic disease other than obesity. Liver disease and
thyroid dysfunction were specifically excluded by biochemical
work-up. All subjects had normal serum creatinine levels.
Measurements. Subjects were studied in the post-absorptive
state. Body weight was measured with a digital scale to the nearest
0.1 kg, and height was measured to the nearest 0.1 cm with a
Holtain stadiometer (Holtain Ltd., Crymych, UK).
Blood pressure was measured in the supine position on the right
arm after a 10-min rest; a standard sphygmomanometer of
appropriate cuff size was used and the first and fifth phases were
recorded. Values used in the analysis are the average of three
readings taken at 5-min intervals.
Insulin sensitivity. Insulin sensitivity was measured using
the frequently sampled intravenous glucose tolerance test
(FSIVGTT) on a different day. In brief, basal blood samples were
drawn at –15 and –5 min, after which glucose (300 mg/kg body
wt) was injected over 1 min starting at time 0. At 20 min, regular
insulin (Actrapid, Novo, Denmark; 0.03 U/kg) was injected as a
bolus. Additional samples were obtained from a contralateral
antecubital vein at times 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 20,
22, 23, 24, 25, 27, 30, 40, 50, 60,70, 80, 90, 100, 120, 140, 160,
and 180 min. Samples were rapidly collected via a three-way
stopcock connected to a butterfly needle. Data from the
FSIVGTT were submitted to computer programs that calculate
the characteristic metabolic parameters by fitting glucose and
insulin to the minimal model that describes the times course of
glucose and insulin concentrations. The glucose disappearance
model, by accounting for the effect of insulin and glucose on
glucose disappearance, provides the parameters SI (10–4) per
minute per microunit per milliliter) or the insulin sensitivity index,
a measure of the effect of insulin concentrations above the basal
level to enhance glucose disappearance. The estimation of model
parameters was performed according to the MINMOD computer
program [19], as previously described [20].
Cohort 2
From January 2010 to February 2012, we consecutively
recruited subjects from the ongoing multicenter FLORINASH
Project. Inclusion criteria were age 30 to 65 years, body mass
index (BMI).30 kg/m2, and ability to understand study proce-
dures. Exclusion criteria were systemic disease, infection in the
previous month, serious chronic illness, .20 g ethanol intake per
day, or use of medications that might interfere with insulin action.
Control non-obese men and women were also included. The
institutional review board approved the study protocol, and all
subjects provided informed written consent.
Study Protocol. Each patient underwent anthropometric
measurements, vascular and abdominal ultrasound, and laborato-
ry parameters on the same day. After 8 h fasting, blood was
obtained for measurement of plasma lipids, glucose, and insulin.
Glucose and lipid levels were determined by standard laboratory
methods. Serum insulin was measured by radioimmunoassay, as
previously described [20]. Insulin resistance was determined by the
homeostasis model assessment of insulin resistance (HOMA-IR).
Body Fat and bone mineral density. Fat mass and bone
mineral density were determinated by dual energy x-ray absorp-
tiometry (DEXA), using a Lunar Prodigy Full Oracle (GE
Healthcare, enCore software version 13,2). Whole body compo-
sition (fat mass, fat-free soft tissue mass and bone mineral content)
was obtanined according to standard procedures, by trained
personnel. Bone mineral density was measured in lumbar spine
(L1–L4) and in distal radius (radius UD), using Word Health
Organization T-score criteria for Caucasian population [21].
Ultrasound Evaluation. We used a Siemens Acuson S2000
(Mochida Siemens Medical System, Tokyo, Japan) ultrasound
system with a 3.5 MHz convex transducer to scan the liver and a
7.5 mHz linear array transducer to scan carotid arteries. Images
were transferred to Starviewer software, developed in our
laboratory (http://gilab.udg.edu), and independently evaluated
by two radiologists blinded to clinical and laboratory data.
Carotid arteries were evaluated according to the Mannheim
Consensus [22]. c-IMT values were manually measured in the far
wall of each common carotid artery in two locations a) in a
proximal segment and b) in a plaque-free segment 10 mm from
the bifurcation. The mean c-IMT value for each subject was
calculated from these four measurements.
Study of the effects of weight loss
An independent cohort composed of 10 Caucasian obese men
attending the Endocrinology Department at the University Clinic of Navarra
was recruited. Weight loss was achieved by prescription of a diet
providing a daily energy deficit of 500–1000 kcal/d as calculated
from the determination of the resting energy expenditure through
indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba
Linda, California) and multiplication by 1.4 as indicated for
sedentary individual’s to obtain the patient’s total energy
expenditure. This hypocaloric regime allows a safe and steady
weight loss of 0.5–1.0 kg/wk when followed and supplied 30, 54
and 16% of energy requirements in the form of fat, carbohydrates
and protein, respectively.
Ethics statement. The institutional review board, Comite´
d’E`tica d’Investigacio´ Clı´nica (CEIC) from the Hospital de Girona
"Dr Josep Trueta" approved the study protocol, and all subjects
provided informed written consent.
Analytical methods. Serum glucose concentrations were
measured in duplicate by the glucose oxidase method using a
Beckman glucose analyser II (Beckman Instruments, Brea,
California). Intraassay and interassay coefficients of variation were
less than 4% for all these tests. HDL cholesterol was quantified
after precipitation with polyethylene glycol at room temperature.
Total serum triglycerides were measured through the reaction of
glycerol/phosphate/oxidase and peroxidase. Serum insulin was
measured in duplicate in the same centralized laboratory by a
monoclonal immunoradiometric assay (Medgenix Diagnostics,
Fleunes, Belgium). The intra-assay coefficient of variation (CV)
was 5.2% at a concentration of 10 mU/l and 3.4% at 130 mU/l.
The inter-assay CVs were 6.9 and 4.5% at 14 and 89 mU/l,
respectively. Osteocalcin was measured by an Enzyme Amplified
FGF-23 and Insulin Resistance
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Sensitivity Immunoassay (EASIA) kit (DRG Instruments GmbH,
Marburg, Germany). Sensitivity of the method, the detection limit,
defined as the apparent concentration two standard deviations
above the average OD at zero binding, was 0.4 ng/ml and the
intra- and inter-assay CV were less than 10%.
FGF23 level in serum was measured by a commercial ELISA
Kit (FGF-23 Elisa Kit; Kainos Laboratories, Inc, Japan) in samples
that were conserved using a protease inhibitor, according to the
manufacturer’s protocol. The intra-assay coefficient of variation
was between 2.0 and 3.0% and the inter-assay coefficient of
variation was between 2.0 and 3.8%. CtFGF23 levels were
measured using a commercial ELISA kit (Human FGF-23 (C-
term) ELISA Kit; Immutopics, Inc; San Clemente, CA) in EDTA
plasma. The intra-assay CV was between 1.4% and 2.4% and the
inter-assay CV was between 2.4% and 4.7%. All FGF23
measurements were centralized in a single laboratory.
Statistical methods. Statistical analyses were performed
using SPSS 12.0 software. Unless otherwise stated, descriptive
results of continuous variables are expressed as mean and SD for
Gaussian variables. Parameters that did not fulfill normal
distribution were logarithmically transformed to improve symme-
try for subsequent analyses. The relation between variables was
analyzed by simple correlation (Pearson’s test). Multiple linear
regression analyses were performed in a stepwise manner to
predict circulating FGF-23 concentration. Levels of statistical
significance were set at P,0.05.
Figure 1. FGF-23 associations with obesity. a) Linear association analysis between serum intact FGF-23 concentrations and body mass index; b)
serum intact FGF-23 concentration according to obesity status; c) Linear association analysis between serum C-terminal FGF-23 concentrations and
body mass index; d) serum C-terminal FGF-23 concentration according to obesity status. All subjects from both cohort 1 and 2 are included.
doi:10.1371/journal.pone.0058961.g001
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Results
Anthropometrical and biochemical characteristics of subjects
included in cohort 1 and 2 are shown in Table 1 and 2,
respectively. We first explored the possible association of serum
FGF-23 concentrations with obesity. In all subjects as a whole,
serum intact and C-terminal concentrations were linearly and
positively associated with BMI and increased with obesity status
(Figure 1).
In cohort 1, both serum iFGF-23 and CtFGF-23 concentrations
decreased linearly with insulin sensitivity (Figure 2 and Table 3).
While iFGF-23 was associated with serum creatinine, CtFGF-23
was linked to serum ferritin concentration (r =20.20, p = 0.02,
Table 3). Multiple linear regression models were constructed to
predict circulating intact or C-terminal FGF-23 levels, with BMI,
age, serum creatinine, ferritin and insulin sensitivity as dependent
variables. Serum creatinine emerged as the only variable that
contributed to iFGF-23 variance (6%, p = 0.005) while serum
ferritin (p,0.0001) and insulin sensitivity (p = 0.002), but not BMI,
age or serum creatinine contributed to 17% of CtFGF-23
variance.
Cohort 2 included both men and women (Table 2). Serum
CtFGF-23 levels were significantly increased in women vs. men
(71.8633.8 vs. 54.3621.8, p = 0.008) despite men and women
being of similar age (Table 2). In this cohort, circulating CtFGF-23
levels increased with BMI (r = 0.51, p,0.0001), DEXA-fat mass
(r = 0.47, p,0.0001), fasting and post-load serum glucose (r = 0.26,
p = 0.02, and r = 0.29, p = 0.01, respectively), fasting and post-load
serum insulin (r = 0.38, p = 0.003, and r = 0.28, p = 0.03, respec-
tively, Table 4) and insulin resistance (HOMA-IR, r = 0.35,
p = 0.006). Circulating CtFGF-23 levels correlated positively with
serum PTH (r = 0.28, p = 0.01) and negatively with serum vitamin
D levels (r =20.27, p = 0.01) and serum ferritin concentrations
(Figure 3, r =20.43, p,0.0001).
Circulating CtFGF-23 concentration was also positively associ-
ated with bone density in the radius (T-score, r = 0.23, p = 0.04)
and tended to be associated with bone density at the lumbar spine
(T-score, r = 0.21, p = 0.06) but these associations were no longer
significant after controlling for BMI. Interestingly, CtFGF-23
concentration was also positvely associated with the mean value of
the right internal carotid artery intima media thickness (ICAIMT,
r = 0.36, p = 0.002, Figure 3) and of the left ICAIMT (r = 0.25,
p = 0.03). Again, these associations were no longer significant after
controlling for BMI.
Similarly to Cohort 1, serum iFGF-23 levels correlated
significantly with serum creatinine (r = 0.34, p = 0.003) and with
age (r = 0.23, p = 0.04). In addition, serum iFGF-23 levels were
positively associated with serum PTH (r = 0.30, p = 0.007) and
serum phosphate concentrations (r = 0.37, p = 0.003) but not with
the remaining parameters depicted above (r,0.20, p.0.15).
Table 1. Anthropometrical and biochemical characteristics of
the study subjects in Cohort 1.
n 133 men
Age (years) 51.8611.6
BMI (kg/m2) 27.663.5
Waist perimeter (cm) 92.669.8
Systolic blood pressure(mmHg) 127.7614.8
Diastolic blood pressure (mmHg) 80.569.6
Cholesterol (mg/dl) 213.9638.01
LDL-cholesterol (mg/dl) 138.08635.2
HDL-cholesterol (mg/dl) 53.1612.2
Log fasting triglycerides (mg/dl) 1.9760.24
Fasting glucose (mg/dl) 97.5611.2
Post-load glucose OGTT (mg/dl) 135.1645.7
Post-load insulin OGTT (mU/L) 70.4663.7
Log Insulin sensitivity (1024*min21*mU/L) 0.460.2
Log serum ferritin (ng/ml) 2.0960.35
Creatinine (mg/dl) 1.0160.1
PTH (pg/ml) 44614.4
Vitamin D (ng/ml) 21.866.5
Serum phosphate (mg/dl) 3.9360.69
iFGF-23 (pg/ml) 28.867.8
Ct FGF23 (pg/ml) 51620.7
BMI, Body mass index; CRP, C reactive protein, iFGF-23, fibroblast
growthfactor-23, CtFGF-23, C-terminal FGF-23 OGTT, oral glucose tolerance
test; PTH, parathyroid hormone.
doi:10.1371/journal.pone.0058961.t001
Table 2. Anthropometrical, clinical and biochemical
characteristics of the study subjects in Cohort 2.
Men Women p`
n 262 52 -
Age (years) 42.267.4 40.868.6 0.4
BMI (kg/m2) 34.169.5 33.3610.6 0.7
Waist perimeter (cm) 107.8621.8 96.1621.2 0.02
Fat mass (kg) 38.9620.5 40.3618.7 0.7
Systolic blood pressure(mmHg) 136618.5 127.8617 0.05
Diastolic blood pressure
(mmHg)
78.1611.1 71610.1 0.006
Right ICAIMT (mm) 0.5860.12 0.5360.15 0.2
Left ICAIMT (mm) 0.6260.12 0.5460.14 0.02
Radium T-score 0.7 (21–1.7) 0.35 (20.3–1.5) 0.3
Lumbar T-score 20.8 (21.2–0.42) 0.35 (21–1.7) 0.02
Cholesterol (mg/dl) 192.4630.6 197638.7 0.6
LDL-cholesterol (mg/dl) 121.4626.6 116.3633.9 0.5
HDL-cholesterol (mg/dl) 45.8613.2 61.6619.3 ,0.0001
Log fasting triglycerides (mg/dl) 2.0260.2 1.9360.19 0.07
Fasting glucose (mg/dl) 92.1611.2 89.8616.6 0.5
Fasting insulin (mU/L) 7.6 (1.8–12.2) 4.9 (2–9.9) 0.3
Post-load glucose OGTT (mg/dl) 120.4634.9 116.1642.9 0.6
Post-load insulin OGTT (mU/L) 52.5643.9 44.7632 0.4
HOMA 1.91 (0.14–4.76) 1.07 (0.41–2.08) 0.2
Log serum ferritin (ng/ml) 2.360.3 1.5760.4 ,0.0001
Creatinine (mg/dl) 0.8260.14 0.6660.11 ,0.0001
PTH (pg/ml) 48.3614.8 47.9620 0.9
Serum phosphate (mg/dl) 3.260.3 3.3660.4 0.16
Vitamin D (ng/ml) 18.368.39 20.3611.7 0.4
iFGF-23 (pg/ml) 32.769.3 35.1616.2 0.4
CtFGF-23 (pg/ml) 54.4621.8 72.04634.1 0.007
BMI, Body mass index; CRP, C reactive protein, iFGF-23, fibroblast growth
factor-23, CtFGF-23, C-terminal FGF-23, ICAIMT, internal carotid artery intima
media thickness, OGTT, oral glucose tolerance test; PTH, parathyroid
hormone. Values are given as mean 6 SD or as median (interquartile range).
doi:10.1371/journal.pone.0058961.t002
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In a multiple linear regressiona analysis, BMI (P = 0.001) and
serum ferritin (p,0.0001), but not age (p = 0.26), HOMA value
(0.36), creatinine (0.23) or sex (p = 0.98) contributed independently
to 45% of the variance in circulating CtFGF-23 levels. On the
contrary, serum creatinine (p = 0.006), age (p = 0.04), and sex
(p = 0.003), but not BMI (P = 0.11), HOMA (p = 0.65), or serum
ferritin (p = 0.21), contributed independently to 20% of the
variance in circulating iFGF-23 levels.
Weight loss study
Characteristics of the subjects are shown in Online table.
Weight loss led to decreased circulating FGF-23 concentrations
(Figure 4) in parallel to decreased HOMA-IR (Table 5). Post-
weight loss (but not pre-weight loss) circulating FGF-23 concen-
trations were significantly associated with HOMA value.
Conclusions
FGF23 principally functions as a hormone regulating phospha-
turia, suggesting that this circulating factor also mediates secretion
of PTH at least indirectly by regulating serum phosphate. FGF23
induces urinary phosphate excretion by suppressing the expression
of sodium/phosphate cotransporter [1]. In agreement with these
functions, we found that circulating iFGF-23 was positively
associated with serum phosphate and PTH concentrations.
The type of information captured by the intact vs. C-terminal
assay of FGF-23 seems different. The C-terminal ELISA assay can
detect both the intact FGF23 hormone and the C-terminal FGF23
fragment. Some authors [23] have proposed that the C-terminal
FGF23 ELISA captures better the biologically functional FGF23
molecule which is decreasing phosphate reabsorption in the renal
Figure 2. FGF-23 associations with insulin sensitivity. a) Linear association analysis between serum intact FGF-23 concentration and insulin
sensitivity in subjects from cohort 1; b) Linear association analysis between serum C-terminal FGF-23 concentration and insulin sensitivity in subjects
from cohort 1.
doi:10.1371/journal.pone.0058961.g002
Table 3. Linear correlation analysis of the association
between circulating intact and CtFGF-23 levels and selected
variables in Cohort 1.
CtFGF-23 p Intact FGF-23 P
Age 0.06 0.4 0.13 0.12
BMI 0.17 0.06 20.002 0.98
Creatinine 0.09 0.29 0.29 0.001
Ferritin 20.20 0.02 0.009 0.9
Log Insulin sensitivity 20.21 0.02 20.19 0.03
Post-load insulin OGTT 0.23 0.01 0.19 0.03
Serum phosphate 0.17 0.06 0.19 0.03
doi:10.1371/journal.pone.0058961.t003
FGF-23 and Insulin Resistance
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58961
tubules. However, it should be taken into account that C-terminal
FGF23 peptides might display opposite effects. Goetz et al have
described that injection of the FGF23 C-terminal tail peptide into
healthy rats inhibited renal phosphate excretion and induced
hyperphosphatemia [24].
According to our findings, renal function within the normal
range significantly impacts on iFGF-23 concentrations, given the
positive associations with serum creatinine in both cohorts, and the
association with parameters that influence serum creatinine
concentrations, such as age and sex (in multiple linear regression
analysis of Cohort 2).
One of the most consistent findings regarding CtFGF-23 was its
association with serum ferritin levels. Iron has been described to
act on FGF23 pathways by inhibiting the cleavage of the intact
Figure 3. FGF-23 associations with ferritin and intima media thickness. Linear association analysis between serum C-terminal FGF-23
concentration and serum ferritin levels in Cohort 1 (a) and 2 (b); c). Linear association analysis between serum C-terminal FGF-23 concentration and
intima media thickness in subjects from cohort 2.
doi:10.1371/journal.pone.0058961.g003
Table 4. Linear correlation analysis of the association
between serum intact and CtFGF-23 levels and selected
variables in Cohort 2.
CtFGF-23 p Intact FGF-23 P
Age 0.10 0.37 0.23 0.04
BMI 0.52 ,0.0001 0.15 0.16
Creatinine 0.003 0.9 0.34 0.003
Ferritin 20.43 ,0.0001 0.07 0.5
HOMA 0.35 0.006 0.17 0.1
Post-load insulin OGTT 0.28 0.03 0.18 0.1
Serum phosphate 0.16 0.2 0.37 0.003
doi:10.1371/journal.pone.0058961.t004
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FGF23 molecule and in assisting the clearance of FGF23
fragments by the kidney [23,25]. Thus, the higher the iron stores,
the lower the CtFGF-23 concentration. And vice versa, the lower
the ferritin levels, the higher the CtFGF-23 levels. Iron deficiency
has been described to stimulate HIF1a leading to increased FGF-
23 transcription [25,26].
We here show tha serum intact and C-terminal increase linearly
with BMI and obesity status. This finding suggest that increased
bone strain with increased adiposity might lead to increased
secretion of FGF-23. Subjects with morbid obesity showed the
highest (almost 2-fold) CtFGF-23 levels, being BMI the factor that
most contributed to its variance. In agreement with this finding,
some studies have shown show a positive correlation of FGF23 and
body weight and fat tissue content in elderly men. For instance, a
significant correlation between intact FGF23 and body weight
(r = 0.13, p,0.0001) was found in 3014 Swedish men aged 69–80
years [18,27]. In another study, participants in the highest
category of BMI had 9.5 RU/ml higher C-terminal FGF23 than
those in the lowest [28]. In 48 perimenopausal obese women and
in 29 nonobese controls, iFGF-23 concentrations correlated
significantly with BMI (r = 0.292) and fat content (r = 0.259) in
all study subjects [29]. A recent case-control study was performed
in 20 women having bariatric surgery and 20 control women
matched for race and age. FGF23 was higher in the bariatric
patients than the controls [30]. There is no mention of the assay
employed. Interestingly, in experimental studies, leptin stimulated
FGF23 expression in bone and suppressed renal 1alpha,25-
dihydroxyvitamin D3 synthesis in leptin-deficient mice [31].
Insulin sensitivity, using a robust measurement as the minimal
model method, also contributed independently to the variance of
serum CtFGF-23 levels in Cohort 1 in which only men with
BMI,40 kg/m2 and a wide range of insulin action were included.
There is only one study, to our knowlege, investigating the
association with insulin sensitivity. Using HOMA value, Wojcik M
et al. found a preliminar association of iFGF-23 with insulin
resistance in obese adolescents [32]. In line with these results,
acute hyperinsulinemia has beeen described to increase serum
FGF-23 concentrations in type 2 diabetes patients [33].
Thus it can be concluded that the most obese, insulin resistant
subjects with low iron stores exhibit the highest FGF-23
concentrations, as measured by the C-terminal assay. It is
tempting to speculate that the mechanical shear stress and loading
of obesity interact with the relative hypoxia of low iron stores on
bone to secrete FGF-23.
That extreme obesity was important in determining CtFGF-23
concentrations was also confirmed by the findings regarding bone
density and carotid intima media thickness. Although CtFGF-23
correlated positively with these parameters, these associations were
no longer significant when BMI was taken into account. In
addition, weight loss led to decreased FGF-23 concentrations.
In the aforementioned study [27], there was a weak but
significant correlation between intact FGF23 and bone mineral
density in femoral neck (r = 0.04, p,0.05), femoral trochanter
(r = 0.05, p = 0.004), total hip (r = 0.06, p = 0.0015) and lumbar
spine (r = 0.07, p = 0.0004). As in the current study, the
associations became insignificant in all regions when adjusting
for established confounding variables including age, height and
weight [27].
Circulating FGF-23 concentration has also been described to be
associated with several cardiovascular risk factors and atheroscle-
rosis [13–18]. We here characterize that this association depends
on the FGF-23 assay and on the presence of morbid obesity.
In summary, there is a differential association of circulating
FGF-23 concentration with parameters of glucose metabolism,
bone density and atherosclerosis that is dependent on iron and
obesity status. It remains to be determined, which signals, other
than phosphate, regulate FGF23 production and which molecules
mediate its regulation.
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